Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
294 Cards in this Set
- Front
- Back
- 3rd side (hint)
Antimicrobials: Combinations used(general)?
|
Additive (1+1=2)
Synergist (1+1>2) Antagonist (1+1<2) |
|
|
Antimicrobial combination: Synergistic combinations?
|
Synergistic combination=
Penicillins+Aminogycosides (Cidal + Cidal) |
|
|
Antimicrobial combination: Antagonistic combinations?
|
Penicillins + Tetracyclins
(Cidal+ Static) |
|
|
Cidal + Static drugs ____(should/should not) be combined
|
Should not
NEVER COMBINE STATIC+CIDAL |
|
|
Bacterial cell wall synthesis inhibitors: Name the drugs/drug classes?
|
1. Penicillins
2. Cephalosporins 3. Imipenem 4. Meropenem 5. Aztreonam 6. Vancomycin |
|
|
Bacterial protein synthesis inhibitors: Name the drugs/drug classes?
|
1. Aminoglycosides
2. Chloramphenicol 3. Macrolides 4. Tetracyclines 5. Streptogramins 6. Linezolid (CLE TAG) |
|
|
Bacterial nucleic acid synthesis inhibitors: Name the drug/drug classes?
|
1. Fluoroquinolones
2. Rifampin |
|
|
Bacterial folic acid synthesis inhibitors: Name the drug/drug classes?
|
1. Sulfonamides
2. Trimethoprim 3. Pyrimethamine |
|
|
Mechanism of resistance against penicillin and cephalosporins?
|
1. Beta lactamases production
2. Change in PBP structure 3. Change in porins |
|
|
Mechanism of resistance against aminoglycosides?
|
Formation of enzymes that inactivate the drug through the process of ______ via
1. _____ 2. _____ 3. _____ |
Through the process of "conjugation" via:
1. Acetylation 2. Adenylylation 3. Phosphorylation |
|
Mechanism of resistance against Macrolides?
|
1. Methyltransferase formation--> Alters binding site on 50S ribosomal subunit
2. Active transport out of the cell |
|
|
Mechanism of resistance against Tetracyclines?
|
Increased P-glycoprotein pump that pumps drugs out of the cell
|
|
|
Mechanism of resistance against Sulfonamides?
|
1. Altered enzyme sensitivity to action of binding drug
2. Use of exogenous folic acid 3. Increased formation of PABA |
|
|
Mechanism of resistance against Fluoroquinolones?
|
1. Altered enzyme sensitivity to action of binding drug
2. Increased activity of transport system to promote drug efflux |
|
|
All bacterial cell wall synthesis inhibitors are _____ (bactericidal/bacteriostatic)?
|
Bactericidal
|
|
|
Penicillins: MOA?
|
1. Bind to PBP
2. Inhibition transpeptidation --> 3. Inhibition of cross-linking |
|
|
Microbes associated with:
1. Penicllinase activity? 2. PBP structure alteration? 3. Porin structure alteration? |
1. Penicillinase: Staph
2. PBP alteration: Pneumococci, MRSA 3. Porins: Pseudomonas |
|
|
Narrow spectrum b-lactamase sensitive group of penicillin drugs: Name em.
|
1. Penicillin G
2. Penicillin V |
|
|
Narrow spectrum b-lactamase sensitive group of penicillin drugs: Spectrum of activity?
|
1. TREPONEMA PALLIDUM
2. Streptococci 3. Pneumococci 4. Meningococci |
|
|
Narrow spectrum b-lactamase resistant group of penicillin drugs: Name em.
|
1. Methicillin
2. Nafcillin 3. Oxacillin 4. Cloxacillin |
|
|
Broad spectrum b-lactamase sensitive group of penicillin drugs: Name em.
|
1. Amoxicillin
2. Ampicillin |
|
|
Broad spectrum b-lactamase sensitive group of penicillin drugs:
Spectrum of activity? |
1. All gram +ves(except staph)
2. E-coli 3. H.influenza 4. Listeria monocytogenes 5. Borellia burgdorferi 6. H.pylori |
|
|
Ampicillin/amoxicillin not effective against _____ (gram +ve cocci)
|
Staph
|
|
|
Listeria monocytogenes: DOC- ____(Ampicillin/amoxicillin)
|
Ampicillin
"LASER- listeria amplification" |
|
|
H.Pylori: DOC-
____(Ampicillin/amoxicillin) |
Amoxicillin
|
|
|
Borellia burgdorferi: DOC- ____(Ampicillin/amoxicillin)
|
Amoxicillin
|
|
|
Extended spectrum b-lactamase sensitive group of penicillin drugs
|
1. Ticarcillin
2. Piperacillin 3. Azlocillin 4. Carbenicillin Extended spectrum activity against? |
Pseudomonas
|
|
Suicide inhibitors:
Name em. MOA? |
Clavulanic acid
Sulbactam Tazobactam MOA: Irreversibly inhibits b-lactamase |
|
|
Penicillin group of drugs- synergy observed with?
|
Aminoglyosides
|
|
|
Penicillins -mechanism of elimination?
Implication? |
Active tubular secretion in kidney
Renal excretion implies dose reduction in renal failure Exceptions? |
Exceptions:
1. Nafcillin 2. Oxacillin (Nafcillin Oxacillin: NO are NOT excreted through kidneys. |
|
Mechanism of elimination of Nafcollin and Oxacillin?
|
Through bile
Implication? |
Nafcillin and Oxacillin cannot be used in liver dysfunction
|
|
Penicillin available in repository form?
|
Benzathine penicilline G
|
|
|
Penicillin with long half life?
|
Benzathine penicillin
T1/2: 2 weeks |
|
|
Penicillin hypersenstivity: type?
|
ALL types
Type I,II,III,IV Type I: 1. Laryngospasm 2. Anaphylaxis 3. Angioedema Type II: 1. Vasculitis 2. Neutropenia 3. Positive coomb's Type III: 1. Vasculitis 2. Serum sickness 3. Interstitial nephritis Type IV: 1. Urticarial/Maculopapular rash. 2. SJS |
|
|
Identify type of hypersensitivity for:
1. Urticaria 2. Positive Coomb's test 3. Angioedema 4. Serum sickness 5. SJS 6. Interstitial nephritis 7. Vasculitis 8. Laryngospasm 9. Neutropenia 10. Anaphylaxis 11. Maculopapular rash |
1. Urticaria: Type IV
2. Positive Coomb's: Type II 3. Angioedema: Type I 4. Serum sickness: Type III 5. SJS: Type IV 6. Interstitial nephritis: Type III 7. Vasculitis: Type II and Type III 8. Layngospasm: Type I 9. Neutropenia: Type II 10. Anaphylaxis: Type I 11. Maculopapular rash: Type IV |
|
|
Penicillins: Adverse reactions?
|
1. Hypersensitivity reactions (I thru IV)
2. Interstitial nephritis 3. NVD 4. Jarisch-Herxheimer reaction |
|
|
Interstitial nephritis commonly observed with which penicillin?
|
Methicillin
|
|
|
Jarisch herxheimer reaction commonly observed with which penicillin?
|
In rx with penicillin for syphilis
|
|
|
GI distress commonly observed with which penicillin?
|
Ampicillin
Why? |
Ampicillin is poorly absorbed in the gut
|
|
Jarisch Herxheimer reaction?
|
Observed in treatment of syphilis: Immune response observed after destruction of t.pallidum and release of antigens
1. Fever 2. Swelling 3. Joint pain |
|
|
Very long acting penicillin?
|
Benzathine penicillin
How is it adminstered (what form)? |
1. IM- thick suspension slow release
(Slow release) "BenzaThick penicillin- thick slow release suspension"--> Long t1/2 |
|
Cephalosporin: MOA?
|
1. Bind to PBP
2. Inhibition transpeptidation --> 3. Inhibition of cross-linking |
|
|
First generation cephalosporin: Name em?
|
1. Cefazolin
2. Cephalexin All Cephalosporins with "ph"s instead of "f"s Spectrum of activity? |
1. Gram +ve COCCI
2. Ecoli 3. Kliebsella 4. Proteus Evade the Problematic Fight Klub |
|
Cephalosporin generation I: unique pharmacokinetic property?
|
Do not enter the CNS
|
|
|
Cephalosporin generation I:
Use? |
In surgical prophylaxis (due to its broad spectrum of activity)
|
|
|
Cephalosporin generation II: Name em?
|
Cefotetan
Cerfuroxime Cefaclor Spectrum? |
increased -ve coverage
|
|
Cephalosporin generation II drug that crosses the BBB?
|
Cefuroxime
|
|
|
Cephalosporin generation III: Name em?
|
1. Cephtriaxone
2. Cephotaxime 3. Cephoperazone 4. Cefdinir "Tried tax per dinar" |
|
|
Cephalosporin: elimination?
|
All eliminated through active tubular secretion via kidneys except
______? |
1. Ceftriaxone
2. Cefoperazone Eliminated in bile |
|
Cephalosporins: Side effects?
|
1. Hypersensitivity reactions etc
same as penicillins 2. Disulfiram like effects observed with |
1. Cefotetan
2. Cefoperazone |
|
Drug fever _____common/uncommon with cepahlosporins?
|
common
|
|
|
Cephalosporin generation III: drug that does not cross the BBB?
|
Cefoperazone
|
|
|
Cpehalosporin generation III: Use?
|
Empiric management of:
1. Meningitis 2. Sepsis |
|
|
Cephalosporin generation IV: properties?
|
1. Wide spectrum
2. B-lactamase resistant 3. Crosses BBB |
|
|
Organisms not covered by cephalosporins?
|
Listeria
Atypicals(mycoplasma/chlamydia) MRSA Enterococci |
|
|
Imipenem/meropenem: MOA?
|
Similar to penicillin
|
|
|
Imepenem and meropenem are beta-lactamase _____sensitive/resistant?
|
Resistant
|
|
|
Imepenem/meropenem: spectrum of activity?
|
1. Effective against all microbes
2. Gram +ve cocci 3. Gram -ve rods 4. Anaerobes |
|
|
Imepenem/meropenem: use?
|
In severe life-threatening infections
|
|
|
Imipenem is always administered with ____?
|
Cilastin
why? |
Cilastin inhibits renal de-hydrpeptidase(breaks down imepenem-->nephrotoxic compound)
1. Increases half life of imepenem 2. Also prevents nephrotoxicity |
|
Drugs used in empiric Rx of life threatening sepsis/meningitis?
|
1. IIIrd generation cephalosporins
2. Imipenem/Meropenem |
|
|
Imipenem/meropenem: elimination?
|
Through the kidney
|
|
|
Imepenem/meropenem: adverse effects?
|
1. GI distress
2. Drug fever 3. CNS effects- (seizures with imipenem) |
|
|
Aztreonam : MOA?
|
Same as penicillins
|
|
|
Penicillin/related drugs resistant to beta-lactamase
|
1. Nafcillin/cloxacillin/oxacillin/Methicillin
2. Cefapime(IV generation cephalosporin) 3. Imepenem/meropenem 4. Aztreonam |
|
|
Penicillin/cephalosporin/related drugs cleared through bile?
|
1. Nafcillin
2. Oxacillin 3. Ceftriaxone 4. Cefoperazone |
|
|
Penicillin/cephalosprin/related drugs safe in renal impairment?
|
1. Nafcillin
2. Oxacillin 3. Ceftriaxone 4. Cefoperazone |
|
|
Cephalosporins that do not have CNS entry?
|
1. Ist generation cephalosporins
2. IInd generation cephalosporins (except cefuroxime) 3. Cefoperazone |
|
|
Cephalosporins used in empirical treatment of meningitis/sepsis?
|
IIIrd generation cephalosporin
|
|
|
Wide spectrum cephalosporin?
|
Cefepime
Mode of administration? |
IV
|
|
IIIrd generation cephalosporins: modes of administration of each drug?
|
1. Ceftriaxone: IM
2. Cefotaxime: Parenteral 3. Cefoperazone: ? 4. Cefdinir: Oral 5. Cefixim: Oral |
|
|
Cephalosporins used for surgical prophylaxis?
|
Ist generation
|
|
|
Cell wall synthesis inhibitor associated with seizures?
|
Imipenem
Also associated with? |
Nephrotoxicity
|
|
Cell wall synthesis inhibitor active mainly against gram -ve rods?
|
Aztreonam
|
|
|
Cell wall synthesis inhibitor that has no cross-reactions with penicillins therefore can be used in patients with hypersensitivity to penicillins?
|
Aztreonam
|
|
|
Aztreonam: Mode of administration?
|
IV
|
|
|
Vancomycin : MOA?
|
1. Binding to D-ALA D-ALA muramyl pentapeptide
2. Inhibits transglycosylation--> 3. Inhibition of peptidoglycan chains. |
|
|
Vancomycin spectrum of activity?
|
1. MRSA
2. Enterococci 3. Clostridium difficile |
|
|
Pseudomembranous colitis: DOC?
|
#1 Metronidazole
#2 Vancomycin |
|
|
Vancomycin resistance?
|
Change of D-ALA to D-Lactate
"D-luck shields" |
|
|
Vancomycin: Administration?
|
IV
|
|
|
Vancomycin ____(can/cannot) cross the BBB?
|
Cannot
|
|
|
Vancomycin : elimination?
|
Through kidneys
|
|
|
Vancomycin: Side effects?
|
1. Red man syndrome
2. Ototoxicity 3. Nephrotoxicity Red man syndrome? Hypersensitivity type? |
Red discoloration of skin due to flushing from histamine release
Type I hypersensitivity |
|
Protein synthesis inhibitor associated with inhibition of initiation complex formation?
|
1. Aminoglycoside
2. Linezolid |
|
|
Protein synthesis inhibitor associated with inteterference with t-rna attachment to A-site?
|
1. Tetracyclines
2. Dalfopristine 3. Quinopristine |
|
|
Protein synthesis inhibitor associated with inhibition of peptidyl transferase enzyme(peptide bond formation?
|
Chloramphenicol
|
|
|
Protein synthesis inhibitor associated with inhibition of translocation?
|
1. Macrolides
2. Clindamycin |
|
|
Sites of attachment (50s or 30s) for:
1. Aminoglycosides 2. Tetracylines 3. Quinupristine 4. Linezolid 5. Dalfopristine 6. Chloramphenicol 7. Macrolides 8. Clindamycin |
1. Aminoglycoside: 30s
2. Tetracyclines: 30s 3. Quinupristine: 50s 4. Linezolid: 50s 5. Dalfopristine: 50s 6. Chloramphenicol: 50s 7. Macrolides: 50s 8. Clindamycin: 50s "CLEan TAg" |
|
|
Aminoglycoside:
MOA? Cidal/static? |
1. Interferes with initiation complex formation
i. Blocks association of 30s with 50s(static) ii. Causes misreading of code(cidal)--> incorporation of from amino acid in protein formation Site of binding (30s/50s)? |
30s
|
|
Tetracyclines:
MOA? Cidal/static? |
Prevents binding of aminoacyl tRNA to acceptor site
Static Site of binding(30s/50s)? |
30s
|
|
Chloramphenicol:
MOA? Cidal/static? |
1. Inhibits formation of peptide bond
2. Inhibits activity of peptidyltranserase Static Site of binding(30s/50s)? |
50s
|
|
Macrolides:
MOA? Cidal/static? |
Inhibit translocation of peptidyl-tRNA from acceptor to donor site (-static)
Static Site of binding(30s/50s)? |
50s
|
|
Aminoglycosides: spectrum of activity?
|
Gram -ve rods
exceptions? |
Anaerobes
|
|
Aminoglycosides are effective/ineffective against anaerobes?
|
Ineffective against anaerobes
Why? |
Since AG utilize O2 dependent pump for uptake by the bacteriae(only present in aerobes)
Absent in anaerobes therefore they are innately resistant |
|
Aminoglycosides are DOCs for?
|
1. Tularemia
2. Bubonic plague (Imagine: Rabbits and baboons eating protein-sugar) |
|
|
Aminoglycosides are used synergistically for _____(organism/infection) with _____(antibiotic)
(2 organisms with 1 combo each) |
Enterococci: PenicillinG + AG
Pseudomonas: Extended spectrum penicillin |
|
|
Aminoglycosides: administration?
why? |
Only IV
Since they are sugars they are water soluble therefore not absorbed orally |
|
|
Aminoglycosides: elimination?
|
Through kidneys
|
|
|
Aminoglycosides: Side effects?
|
1. Nephrotoxicity
2. Ototoxicity 3. Neuromuscular blockade |
|
|
Aminoglycoside drug interaction in relation to nephrotoxicity?
|
1. Vancomycin
2. Cispatin 3. Amphotericin B 4. Cyclosporin |
|
|
Aminoglycoside drug interaction in relation to ototoxicity?
|
1. Loop diuretics
|
|
|
Aminoglycoside: Ototoxicity?
|
1. Hair cell damage
2. Vestibular dysfunction |
|
|
Aminoglycoside: dosing?
|
Once-daily dosing
|
|
|
Aminoglycoside: Nephrotoxicity?
|
1. Proteinuria
2. Hypokalemia 3. Acidosis 4. Acute tubular necrosis |
|
|
Aminoglycoside : NM blockade?
|
1. Decreased release of ACh.
(Similar mechanism to botulinus toxin) 2. Enhance effect of skeletal muscle relaxants |
|
|
Tetracyclines:
MOA? |
Prevents attachment of t-RNA to A site.
--> Therefore prevent ELONGATION of proteins Static |
|
|
Aminoglycosides : Name em?
|
1. Gentamicin
2. Tobramicin 3. Amikacin 4. Streptomycin |
|
|
Aminoglycoside used topically?
|
Neomycin in preparation "neopsorin"
|
|
|
Aminoglycosides: resistance?
|
Production of conjugase enzyme--> faster elimination
|
|
|
Phototoxicity: Associated antibacterial drugs?
|
1. Tetracyclines
2. Sulfonamides 3. Fluoroquinolones |
|
|
Tetracyclines: DOCs for?
|
1. Borellia burgdorferi
2. Ricketssiae Imagine: "Tet attack on boris yeltsin with a racket" |
|
|
Tetracyclines: other uses?
|
1. Atypicals(superseeded by macrolides)
2. H.pylori 3. Borellia burgdorferi(DOC) 4. Ricketssia(DOC) |
|
|
Tetracycline used in prostatitis?
|
Doxycycline
(doXXycycline for prostatitis) |
|
|
Tetracycline used in meningococcal carrier state?
|
Minocycline
(MINocycline used in MENingitis or MINd/brain/CNS infection) Why? |
Since minocycline attains high concentration in saliva and tears
|
|
Tetracycline used in SIADH?
|
Demeclocycline
MOA? |
Blocks ADH receptor functions in distal tubule
|
|
Tetracycline used in soft tissue infetions/intestinal infections/resistant infections?
|
Tigecycline
|
|
|
Tetracycline used in gingivitis?
|
Minocycline
|
|
|
Tetracycline elimination?
|
Through kidneys except ____?
|
Demeclocycline
(eliminated via liver) |
|
Tetracycline safe in renal impariment?
|
Demeclocycline
(eliminated through liver) |
|
|
Tetracycline: pharmacokinetics?
|
Chelation reduces absorption-
Divalent cations 1. Ca 2. Mg 3. Fe therefore should not be taken with foods- dairy products etc |
|
|
Tetracyclines: Advere effects?
|
1. Tooth-enamel dysplasia
2. Reduced bone growth 3. GI distress 4. Liver dysfunction 5. Vestibular dysfunction |
|
|
Why are tetracyclines C/I in pregnancy?
|
D/T liver dysfunction
|
|
|
Macrolides: DOCs for?
|
1. Atypicals- Chlamydia, Mycoplasma, Ureoplasma,
2. MAC 3. Legionella pneumophilia 4. H.pylori: Clarithromycin |
|
|
Macrolides : Other microbes covered?
|
Gram +ves except ___?
|
MRSA
|
|
Macrolides: Side effects?
|
1. GI distress
2. Reversible deafness at high doses |
|
|
Macrolides: GI distress due to?
|
Stimulation of motilin receptors
|
|
|
Macrolides more commonly associated with GI distress?
|
1. Erythromycin
2. Azithromycin (You "thro" up with aziTHRO and eryTHROmycins) |
|
|
Ketolide?
Use? |
1. Telithromycin
2. Used in macrolide resistant S.pneumonia |
|
|
Clindamycin : MOA?
|
Same as macrolide
Prevents translocation |
|
|
Clindamycin: spectrum of activity?
|
Gram +ve cocci
Anaerobes |
|
|
Is clindamycin effective against MRSA?
|
Yes
|
|
|
Clindamycin: one good use?
|
Osteomyelitis: since it achieves good concentration in bone
(and effective against gram +ve cocci- stapj aureus- MCC of osteomyelitis) |
|
|
Clindamycin: Side effects?
|
***Pseudomembranous colitis***
|
|
|
MCC of pseudomembranous colitis? (which specific antimicrobial agent)
|
Clindamycin
|
|
|
Macrolide resistance?
|
Bases of rRNA get methylated therefore macrolide fails to recognize the binding site.
(Macrolide resistance thru Methylation of bases) |
|
|
Drugs used in osteomyelitis?
|
1. Staph aureus: clindamycin
2. Salmonella: Quinolones 3. Pseudomonas: Quinolones (Salmonella in sickle cell anemia) (Pseudomonas in diabetics and IV drug abusers) |
|
|
Macrolide safe in pregnancy?
|
Azithromycin
(since its water soluble it does not cross the placental barrier) |
|
|
Chloramphenicol: MOA?
|
Inhibits peptidyl transferase
(binds 50S) Bacteriostatic |
|
|
Chloramphenicol: Use?
|
Back up drug for -
1. S.typhi 2. B.fragilis 3. Ricketssia |
|
|
Chloramphenicol: pharmacokinetics?
|
Metabolized by hepatic glucoronidation
therefore dose reduction required in liver dysfunction ***Inhibition of P450*** |
|
|
Chloramphenicol:
Adverse effects? |
1. Gray baby syndrome
2. BM suppression (aplastic anemia) 3. Kernicterus (displaces bilirubin from binding site)-- therefore C/i in children |
|
|
Grey baby syndrome?
|
Observed as an adverse effect of chloramphenicol toxicity in neonates
Reason? |
Chloramphenicol metabolized by glucoronidation in liver.
In neonates the glucoronyl transferase enzyme is relatively deficient-->excess chloramphenicol |
|
Linezolid: MOA?
|
Inhibits formation of initiation complex (prevents formation of N-formymethionine-tRNA-mRNA complex)
|
|
|
Linezolid: use?
Adverse effects? |
Use:
1. VRSA 2. VRE 3. Drug resistant pneumococci Adverse effects: 1. Bone marrow suppression- platelets--> bleeding problems |
|
|
Antimicrobials associated with BM toxicity?
|
1. Tetracyclines
2. Choramphenicol 3. Linezolid(plateles) 4. Trimethoprim 5. Pyrimethamine |
|
|
Quinupristine/Dalfopristine: MOA?
|
1. Similar to tetracycline
2. Prevent interaction between amino-acyl tRNA with acceptor site 3. Stimulate 50S(?) dissociation from tertiary complex |
|
|
Quinupristine/Dalfopristine: Use?
|
Used together parenterally in rx of:
1. VRSA 2. VRE |
|
|
Quinupristine/Dalfopristine: Side effects?
|
Unknown(?)
|
|
|
Folic acid synthesis inhibitors?
|
1. Sulfonamides
2. Trimethoprim 3. Pyrimethamine 4. Methotrexate |
|
|
Sulfonamides inhibit _____ enzyme?
|
Dihydropteroate synthetase
|
|
|
DHF reductase inhibited by?
|
1. Trimethoprim
2. Pyrimethamine 3. Methotrexate |
|
|
Sulfonamides always used in combinations: why?
|
Because of multiple resistance
|
|
|
When are sulfonamides used in combinations?
|
1. Sulfasalazine: Ulcerative colitis and RA
2. Ag-sulfadiazine: burns |
|
|
Sulfasalazine: MOA?
|
sulfasalazine--colonic bacteriae-->
5-ASA(ulcerative colitis) sulfapyridine(RA) |
|
|
Uses of trimethoprim-sulfamethoxazole:
DOC for? others? |
DOC:
1. Nocardia 2. P.Jirovecci prophylaxis 3. Toxoplasma gondii 4. Back up for listeria Others: Gram -ve: Ecoli, salmonella, shigella, H.influenza Gram +ve: staph (including MRSA) |
|
|
Sulfonamides: pharmacokinetics?
|
Hepatically acetylated
Renally excreted High protein binding--> kernicterus |
|
|
Kernicterus causing antimicrobial drugs?
|
1. Chloramphenicol
2. TMP/SMX |
|
|
MRSA effective antimicrobials?
|
1. Vancomycin
2. Clindamycin 3. TMP/SMX |
|
|
Sulfonamides: toxicity?
|
1. SJS
2. Hemolysis in G6PD deficiency 3. Phototoxicity 4. BM suppression |
|
|
Pneumocystis jirovecci: Drugs used?
|
1. Cotrimoxazole
2. Pentamidine 3. Atovaquone |
|
|
Nucleic acid synthesis inhibitors?
|
Fluroquinolones
|
|
|
Fluoroquinolones: MOA?
cidal/static? |
1. Inhibition of DNA gyrase/Topoisomerase II
2. Inhibition of Topoisomerase IV FQs are cidal Topoisomerase IV: function? |
Prevents sister chromatids from twisting and recombining
|
|
Fluoroquinolones used in?
|
1. UTIs- cotri resistant strains
2. STDs-chlamyida gonorrhea 3. PIDs 4. Gram -ve infections 5. Diarrhea(shigella salmonella) 6. Soft tissue infections 7. Drug-resistant pneumococci |
|
|
Drug resistant pneumococci?
|
1. Fluoroquinolone (levofloxacin)
2. Telethromycin |
|
|
Soft tissue infections: drugs used?
|
1. Tigecycline
2. Fluoroquinolones (soFT tissure infections- fluoroquinolones tigecycline |
|
|
Fluoroquinolones: elimination?
|
Eliminated thru active secretion in kidney
(avoid probenicid) (Dose reduction in renal failure) |
|
|
Fluoroquinolones: side effects?
|
1. Tendon rupture
2. Phototoxicity 3. Headache/insomnia/dizziness 4. Inhibition of chondrogenesis 5. Prolongation of QT interval 6. Seizures (tendonitis, phototoxicity chodrogenesis, QT increase, seizures) |
|
|
Drugs whose absorption gets limited due to divalent cations (Fe, Ca)
|
1. Tetracycline
2. Fluoroquinolones |
|
|
Metronidazole:
MOA? Cidal/static? |
Unknown
production of free radicals Cidal |
|
|
Metronidazole is effective against _____(aerobes/anaerobes) ?
|
anaerobes
|
|
|
Metronidazile effective against ____(gram +ve/-ve)
|
gram -ve
Effective against which gram +ve? |
Clostridium
|
|
Metronidazole DOC for?
|
Clostridium difficile
(Pseudomembranous colitis) |
|
|
Metrinodazole: Side effects?
|
1. Metallic taste(d/t gingivitis)
2. Disulfiram effect |
|
|
A/tb drugs: Name em?
|
1. Isoniazid
2. Rifampin 3. Ethambutol 4. Pyrazinamide 5. Streptomycin |
|
|
Isoniazid
MOA? Resistance? |
Inhibits mycolic acid synthesis (cell wall synthesis)
Resistance by: Deletions in Kat gene(catalase gene)--> no catalase production ---> no more conversion of isoniazid to active form |
|
|
Isoniazid: side effects?
|
1. Hepatitis(elevated AST and ALT)
2. Peripheral neuritis 3. Sideroblastic anemia 4. SLE(in slow acetylators) |
|
|
Rifampin: MOA?
|
Inhibition of DNA dependent RNA polymerase
(Nucleic acid synthesis inhibitor) |
|
|
Rifampin: Side effects?
|
1. Red orange urine/saliva
2. Hepatitis 3. Induction of P450 |
|
|
Ethambutol: MOA?
|
Inhibition of arabinogalactan synthesis(cell wall component)
|
|
|
A/tb drug requiring conversion by catalase? (prodrug)
|
Isoniazid
|
|
|
Ethambutol: Side effects?
|
1. Dose dependent retrobulbar neuritis
2. Decreased visual acuity (red-green discrimination) |
|
|
Pyrizinamide: MOA?
|
Unknown
|
|
|
Pyrizinamide: side effects?
|
1. Hepatitis
2. Hyperuricemia |
|
|
Streptomycin: MOA?
|
AG: initiation complex formation inhibition
misreading of genetic code |
|
|
Streptomycin: adverse effects?
|
1. Vestibular toxicity
2. Deafness 3. Nephrotoxicity 4. NM blockade |
|
|
A/tb drug associated with hepatitis?
|
1. Isoniazid
2. Rifampin 3. Pyrizinamide |
|
|
A/tb drug which is a prodrug?
|
Isoniazid
|
|
|
A/tb drug which is associated with:
1. Retrobulbar neuritis 2. Red-orange metabolites 3. Hyperuricemia 4. Peripheral neuritis 5. Deafness 6. Sideroblastic anemia 7. Induction of P450 |
1. Retrobulbar neuritis: Ethambutol
2. Red orange metabs: Rifampin 3.Hyperuricemia: Pyrizinamide 4. Peripheral neuritis: Isoniazid 5. Deafness: Streptomycin 6. Sideroblastic anemia: Isoniazid 7. Induction of P450: Rifampin |
|
|
Isoniazid prophylaxis offered to which patient population
? |
1. Young children on exposure even if TST negative
2. TST conversion in past 2 years 3. Tuberculin reactors with high risk (diabetes/HIV/leukemia/prolonged glucocorticoid) |
|
|
Amphotericin B: MOA
|
Interaction with cell membrane--->Pore formation(polyene)
|
|
|
Amphotericin B: Spectrum of activity/DOC for?
|
Wide spectrum: DOC for- 1.Aspergillus 2.Candida 3.Cryptococcus 4. Histoplasma 5.Mucor
|
|
|
Polyenes: Name em?
|
Amphotericin B
Nystatin |
|
|
Nystatin: MOA?
|
Polyene: "interact with fungal cell membrane" ---> "pore" formation altering membrane permeability
|
|
|
Amphotericin B: MOA
|
Interaction with cell membrane--->Pore formation(polyene)
“Polyenes produce Pores in membranes” |
|
|
Amphotericin B: Spectrum of activity/DOC for?
|
Wide spectrum: DOC for-
1.Aspergillus 2.Candida 3.Cryptococcus 4. Histoplasma 5.Mucor 6. Sporothrix |
|
|
Amphotericin B: MOA has synergistic action with _____?
|
Flucytosine in _____ and _____ fungal infections
|
1. Candida
2. Cryptococcus |
|
Nystatin : Uses?
|
Used in topical infections only
Why cannot it be used systemically? |
Because of its high toxicity- cannot be used systemically
|
|
Amphotericin B : Pharmacokinetics? (unique)
|
1. Given IV(poor absorption)
2. Poor CNS penetration 3. Can be administered intra-thecally 4. Slow clearance- long T1/2 |
|
|
Amphotericin B: Side effects?
|
1. Fever/chills
2. Hypotension (d/t histamine) 3. Nephrotoxicity(dose dependent) 4. Anemia (due to less erythropoetin) 5. Renal tubular acidosis and hyperkalemia(nephrotoxicity) Precautions to observed |
|
|
Azoles: MOA?
|
Inhibition of P-450 enzyme 14-alpha-demethylase
Function of 14-alpha-demethylase: function? |
Converts lanosterole-->erogsterole
|
|
Azoles: Resistance development?
|
Decreased intracellular accumulation of azoles (Formation of pumps)
|
|
|
DOC for paracocidioides?
|
Ketoconazole
Other uses of ketoconazole? |
Other uses:
1. Back up for histoplasma 2. Mucocutaneous candidiasis 3. Dermatophytoses 4. Back up for blastomyces |
|
DOC for:
1. Sporotrichoses 2. Aspergillosis 3. Paracoccidioides 4. Histoplasmosis 5. Candida(systemic) 6. Candida(mucocutaneous) 7. Blastomycosis 8. Cryptococcosis 9. Aspergillosis 10. Mucor 11. Coccidiodomycosis 12. Candida(topical) 13. Meningeal fungal (any) 14. Used in combination with amphotericin B 15. Esophageal candidiasis? |
1. Sporotrichosis: Itraconazole/Voriconazole
2. Aspergillosis: Itraconazole/Voriconazole 3. Paracoccidioides: Ketoconazole 4. Histoplasmosis: Amphotericin B 5. Candida (systemic): Amphotericin B 6. Candida (muco-cutaneous): Flucanazole 7. Blastomycosis:Itraconazole/voriconazole 8. Cryptococcosis: Amphotericin B 9. Aspergillosis: Itraconazole/voriconazole 10. Mucor: Amphotericin B 11. Coccidiodomycosis: Flucanazole 12. Candida (topical): Clotrimazole/nicomazole 13. Meningeal fungal(any): Flucanazole 14. Used in combination with amphotericin B: Flucytosine 15. Esophageal candidiasis: Flucanazole |
|
|
Flucanazole: DOC for?
|
1. Esophageal candidiasis
2. Invasive candidiasis 3. Coccidiodomycosis 4. Fungal meningitis (cryptococcal) |
|
|
Itraconazole/Voriconaxole: DOC for?
|
1. Blastomycosis
2. Sporotrichosis 3. Aspergillosis (Imagine casper near a volcanic blast from the spore crater) |
|
|
Azoles used topically?
|
1. Clotrimazole
2. Miconazole |
|
|
Azoles that penetrate CNS?
|
Only flucanazole
|
|
|
Absorption of ketoconazole is interfered by ____?
|
Antacids
|
|
|
Azole whose absorption is increased by food?
|
Itraconazole
|
|
|
Azoles metabolized by liver enzymes?
|
Ketoconazole and itraconazole
|
|
|
Azole that is eliminated from liver in an unchanged form?
|
Flucanazole
|
|
|
Azoles: side effects?
|
I. Decreased synthesis of steroids(cortisol/testorsterone)-->
1. Decreased libido 2. Gynecomastia 3. Menstrual abnormality II. Hepatotoxicity: Increased LFTs |
|
|
Flucytosine: the 2 MOAs?
|
1. Formation of 5-FU--(triphosphorylation)--->incorporated into fungal RNA
2. 5-FU---->5-fd-UMP (inhibits thymidylate synthase)--->decreased thymine |
|
|
Flucytosine always used in combination with ______?
|
Amphotericin B
Why? |
Due to rapid development of resistance
|
|
Flucytosine and amphotericin B combination used in _____ and _____fungal infections
|
Cryptococcal and Candidal
|
|
|
Flucytosine: side effects?
|
Bone marrow toxicity
|
|
|
Griseofulvin: MOA?
|
Disrupts microtubule structures of _____?
|
Dermatophytes
|
|
Griseofulvin attains maximum concentration in _____(body part/structure)
|
Keratin
|
|
|
Griseofulvin: side effect?
|
Disulfiram like reaction
|
|
|
Terbanafine: MOA?
|
Inhibits squalene epoxide ---> decreased ergosterole synthesis
(cell wall synthesisn inhibitor) |
|
|
Terbanafine: Side effects?
|
1. GI distress
2. Hepatotoxicity (increased LFT) |
|
|
Caspofungin/Micafungin: MOA?
|
Inhibit glucan synthesis needed in cell wall synthesis
|
|
|
Caspofungin/Micafungin: Uses?
|
1. Invasive candidiasis
2. Aspergillosis |
|
|
Caspofungin/Micafungin: Side effects?
|
1. GI distress
2. Flushing |
|
|
Antivirals that inhibit viral penetration?
|
1. Enfuvirtide
2. Maraviroc 3. Amantadine |
|
|
Antivirals that inhibit uncoating?
|
Amantadine
|
|
|
Antivirals that inhibit DNA-polymerase?
|
1. Acyclovir
2. Foscarnet 3. Ganciclovir |
|
|
Antivirals that inhibit RNA-polymerase?
|
1.Foscarnet
2. Ribavarin |
|
|
Antivirals that inhibit viral reverse trascriptase?
|
1. Zidovudine
2. Didanosine 3. Zalcitabine 4. Lamivudine 5. Stavudine 6. Lamivudine 7. Nevirapine 8. Efavirenz |
|
|
Antivirals that inhibit aspartate protease?
|
1. Indinavir
2. Ritanavir 3. Saquinavir 4. Nelfinavir |
|
|
Antivirals that inhibit neuraminidase?
|
1. Zanamavir
2. Oseltamavir |
|
|
Acyclovir: MOA?
|
1. Monophosphorylated by viral thymidine kinase-->bioactivated by host cell kinase--->triphosphate-->incorporated into DNA-->chain termination (since it lacks 3'hydroxyl group)
2. Acyclovir directly inhibits viral DNA polymerase |
|
|
Acyclovir: Resistance?
|
1. Changes in DNA polymerase
2. Decreased/complete inactivity of thymidine kinase (TK-) |
|
|
Acyclovir: use/antiviral?
|
1. HSV
2. VZV only |
|
|
Acyclovir: effect in HSV/VZV?
|
1. Reduces viral shedding(genital herpes)
2. Reduces acute neuritis in shingles 3. Reduces symptoms in chicken pox 4. Prophylactic in immunocompromised patients |
|
|
Acyclovir is ineffective against ______?(herpes condition/symptom)
|
Post herpetic neuralgia
|
|
|
Acyclovir: Side effects?
|
1. Crystalluria
2. Neurotoxicity (headache, confusion, seizures) |
|
|
Crystalluria observed as acyclovir side effect can be minimized by?
|
Maintaining hydration
|
|
|
Is acyclovir hematotoxic?
|
No
|
|
|
Antivirals with DNA-polymerase activity that are used in acyclovir resistant cases?
|
1. Foscarnet
2. Valacyclovir |
|
|
Foscarnet and valacyclovir can be used in TK-ve strains: true/false?
|
FALSE
|
|
|
Foscarnet and valacyclovir: pharmacologoc advantage over acyclovir?
|
Have a longer T1/2
|
|
|
Ganciclovir: MOA?
|
1. First step: phophorylation by Thymdine kinase/UL-97----> activated form--->incorporated into DNA--->termination
2. Activated gancyclovir inhibits DNA polymerase directly |
|
|
Ganciclovir: Resistance?
|
1. Change in DNA polymerase
2. TK-ve strains |
|
|
Ganciclovir: Side effects?
|
1. Hematotoxicity(leukopenia/thrombocytopenia)
2. Crystalluria 3. Mucositis 4. Fever 5. Rash 6. Siezures in overdose |
|
|
Foscarnet: MOA?
|
Inhibits DNA and RNA polymerase
|
|
|
Antiviral used in prophylaxis and rx of CMV infections?
|
Ganciclovir (CMV retinitis in AIDS and transplant patients)
|
|
|
Ganciclovir: Uses?
|
1. HSV
2. VZV 3. CMV |
|
|
Foscarnet: Side effect?
|
1. Nephrotoxicity: ATN
2. Hypocalcemia: tetany 3. Seizures(hypocalcemia) |
|
|
Foscarnet should be avoided with _____ drug
|
IV pentamidine
Why? |
To avoid life threatening nephrotoxicity and hypocalcemia
|
|
NRTIs?
|
Nucleoside reverse transcriptase inhibitors:
1. NNRTI 2. NRTI |
|
|
Antiviral drug that is not an antimetabolite?
|
Foscarnet
|
|
|
NRTIs: MOA?
|
Activated by nonspecific phosphorylation---> competes with natural nucleotides---> incorporated into DNA---> termination
2. Activated/phosphorylated compound inhibits reverse trancriptase |
|
|
NRTIs: Name em
|
1. Zidovudine 2. Didanosine 3. Zalcitabine 4. Lamivudine 5. Stavudine 6. Lamivudine 7. Nevirapine 8. Efavirenz
|
|
|
NRTIs: Resistance?
|
Occurs due to mutation in gene that encodes for reverse trancriptase
|
|
|
NRTI associated with:
1. Myopathy 2. Peripheral neuropathy 3. Pancreatitis 4. Hematotoxicity 5. GI distress 6. Liver dusfunction 7. Neutropenia? |
1. Myopathy: Zidovudine
2. Peripheral neuropathy: Zidovudine, Zalcitabine, Didanosine, Stavudine 3. Pancreatitis: Zalcitabine, Didanosine 4. Hematotoxicity: Zidovudine 5. GI distress: Lamivudine, Zalcitabine 6. Liver dysfunction: Didanosine 7. Neutropenia: Lamivudine, Zalcitabine |
|
|
Least toxic of all NRTIs?
|
Lamivudine
|
|
|
Protease inhibitors: MOA?
|
Inhibit aspartate protease (required for cleaving pre-proteins into proteins of mature virus
|
|
|
Protease inhibitors: resistance?
|
Mutation in pol gene
|
|
|
Is cross resistance observed amongst protease inhibitors?
|
NO cross resistance between protease inhibitors
|
|
|
Is cross resistance observed amongst NRTIs?
|
NO cross resistance between NRTIs
|
|
|
Protease inhibitors: Name em?
|
1. Indinavir 2. Ritanavir 3. Saquinavir 4. Nelfinavir
|
|
|
2 protease inhibitors always used in combination?
|
Indinavir and ritanavir
Why? |
To avoid resistance
|
|
NRTI combinations to be avoided? Why?
|
1. Didanosine + Zalcitabine(additive toxicity- pancreatitis)
2. Zidovudine + Stavudine(competition for activation) |
|
|
Least toxic of all protease inhibitors?
|
Saquinavir
|
|
|
Protease inhibitor associated with crystalluria?
|
Indinavir
|
|
|
Ritonavir: side effect?
|
Induction of CYPA12. Inhibition of all other P450 enzymes
|
|
|
Protease inhibitors: side effect in general?
|
Lipid and carb metab disorder-->obesity, insulin resistance
|
|
|
Antiviral that inhibits integrase enzyme (HIV)?
|
Raltegravir
|
|
|
Enfuvirtide: MOA?
|
Fusion inhibitor: binds to gp41
|
|
|
Maraviroc: MOA?
|
Inhibition of CCR-5 protein
Location of CCR-5 protein? |
CD4+ T cell
|
|
Amantadine: MOA?
|
Prevents attachment, penetration and uncoating of infuenza A virus
|
|
|
Amantadine: side effects?
|
1. Insomnia
2. Seizures 3. Nervousness 4. Livedo reticularis 5. Atropine like side effects |
|
|
Amantadine: Uses?
|
Mainly for prophylaxis purposes
|
|
|
Zanamavir/oseltamavir: MOA?
|
Inhibit neuraminidase
Neuraminidase : function? |
Prevent clumping of virus particles so that more may be available for infection
|
|
Neuraminidase inhibitors: name em?
|
Zanamavir/oseltamivir
|
|
|
Neuraminidase inhibitors: uses?
|
Used for prophylaxis
|
|
|
Ribavarin: MOA?
|
1. Monophosphorylated form inhibits IMP dehydrogenase
2. Triphosphate inhibits RNA polymerase and end capping of viral RNA |
|
|
Ribavarin: Clinical uses?
|
1. Hepatitis C (Adjunct to alpha interferon)
2. RSV 3. Lassa fever 4. Hanta virus |
|
|
Ribavarin: side effects?
|
1. Hemotoxic
2. Teratogenic |
|
|
Interferon used in
1. Chronic granulomatous disease 2. Multiple sclerosis 3. Hepatitis? |
1. CGD: IFN-gamma
2. MS: IFN-beta 3. Hepatitis: IFN-alpha |
|
|
Uses of alpha IFN?
|
1. Hepatitis
2. Multiple myeloma 3. Renal cell carcinoma 4. Kaposi's sarcoma 5. Chronic myelogenous leukemia |
|
|
antiretroviral combinations used in:
1. HIV prophylaxis for needle stick injury 2. HIV prophylaxis for high risk exposure 3. HIV in pregnancy 4. Intrapartum 5. During delivery? |
1. Zidovudine+Lamivudine
2. Zidovudine+Lamivudine+Indinavir 3. ZDV full dose in 2nd and 3rd trimester 4. Zidovudine 5. Nevirapine |
|
|
DOC for:
1. Amebiasis 2. Giardiasis 3. Trichomoniasis 4. Toxoplasmosis 5. Leishmaniasis 6. Trypanosomiasis |
1. Amebiasis: Metronidazole
2. Giardiasis: Metronidazole 3. Trichomoniasis: Metronidazole 4. Toxoplasmosis: Pyrimethamine + sulfadiazine 5. Leishmaniasis: Stibogluconate 6. Trypanosomiasis: Nifurtimox african: arsenic componds |
|
|
Antimalarials: Chloroquine sensitive: prophylaxis:
|
Chloroquine + primaquine
|
|
|
Antimalarials: Back up drugs?
|
1. Hydroxychloroquine
2. Primaquine 3. Pyrimethamine-sulfadoxine |
|
|
DOC for:
1. P.falciparum 2. P.malaraie 3. P.vivax 4. P. ovale |
1. P.falciparum: Chloroquine
2. P.malariae: Chloroquine 3. P.vivax: Chloroquine + Primaquine 4. P.ovale: Chloroquine + Primaquine |
|
|
Antimalarials: side effects?
|
Hemolysis in G6PD deficiency
Cinchonism with quinine |
|
|
Mebendazole: MOA?
|
1. Decreased glucose uptake
2. Distorts microtubule structure |
|
|
Antimicrobials that distort microtubule structure?
|
1. Mebendazole
2. Griseofulvin |
|
|
Mebendazole: uses?
|
For intestinal nematodes
|
|
|
Praziquantel: MOA?
|
1. Increases Ca influx
2. Increases vacuolization |
|
|
Praziquantel: Use?
|
Most cestodes and trematodes
|
|